Perrigo, Actavis, others file reply against claim splitting in US states' generic drug antitrust case

( April 9, 2025, 18:39 GMT | Official Statement) -- MLex Summary: Perrigo, Actavis, Amneal and other pharmaceutical companies filed a reply in support of a judgment against splitting claims in US states’ case over generic drug pricing. They said that there is no record evidence that the “overarching conspiracy” claim alleged in the last-filed acting is any different from the “overarching conspiracy” claims asserted in earlier-filed actions. “Rather, the states have alleged a singular ‘pervasive,’ ‘industry-wide,’ overarching ‘fair share’ agreement that is ‘broader than the defendant manufacturers named’ in each of the three complaints and was implemented by individual drug-specific conspiracies, each of which was ‘part of [this] larger overarching conspiracy.’” See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.

Know what others in the room don’t, with features including:

Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Perrigo, Actavis, others file reply against claim splitting in US states' generic drug antitrust case

Prepare for tomorrow’s regulatory change, today

Documents

Related Sections